Cigna's Demonstration of “Real World” Effectiveness for Hepatitis C New Drug Therapies Drives Affordability Strategies
Syniverse Holdings SVR posted second-quarter results that mostly met our expectations. We are reiterating our opinion that this company has very little growth potential and no competitive advantage. We continue to be less than positive on the overall market for providing network services to ...
Aethlon Medical® Reports Rapid and Sustained Virologic Response Rates in Hepatitis C (HCV) Treated Patients
Three stocks we think investors should be wary of.